Genentech has reached a memorandum of understanding with JHL Biotech in its civil lawsuit related to the theft of Genentech’s trade secrets.
Genentech has reached a memorandum of understanding with JHL Biotech in its civil lawsuit related to the theft of Genentech’s trade secrets.
According to Genentech, the formal settlement, which remains to be executed, requires JHL to stop developing its biosimilars referencing Genentech’s products: rituximab (Rituxan), dornase alfa (Pulmozyme), trastuzumab (Herceptin), and bevacizumab (Avastin). JHL will also be required to destroy all cell lines and cell banks that are associated with these products, and the biosimilar developer must cease using or sharing any of Genentech’s confidential information. Several of the proposed biosimilars had already entered phase 3 development.
The agreement stems from allegations that Xanthe Lam, formerly employed as a scientist at the Roche Holding AG unit from 1986 until 2017, downloaded, collected, and transferred proprietary information to her husband, Allen Lam, and others at the China-based JHL. She also allegedly secretly consulted for JHL while still employed at Genentech.
In its civil complaint, Genentech pointed to the existence of documentary evidence, “including emails, text messages, Skype logs, and audit records…as well as admissions from [2] of the named defendants,” all of which “make clear that former Genentech employees and others at JHL conspired to give JHL an illegal and corrupt advantage in the biotechnology industry.” The complaint includes a screenshot from Xanthe Lam’s Genentech-issued computer, which shows a folder titled “JHL” that contained subfolders, 4 of which were named for Genentech medicines for which JHL was in the process of developing biosimilars.
Sean Johnston, senior vice president, general counsel, and chief compliance officer of Genentech, said in a statement concerning the agreement, "we're pleased to have secured the return of our property and the prevention of any further dissemination and illegal use. The agreement points to the significance of defending and protecting one's intellectual property rights, trade secrets and other confidential and proprietary information.”
Johnson added, “Leveraging trade secrets and confidential and proprietary information from an employer or a competitor to create an unfair and illegal competitive advantage is a serious crime. Dishonest and illegal actions such as these threaten scientific innovation, obstruct fair competition, and undermine the hard work of our employees and people throughout the industry who act with integrity and in the best interests of patients every day.”
JHL’s executive chairman and chief executive officer, James Huang, said in a statement that “after careful consideration, we determined the settlement provides the best path forward for the company to focus exclusively on delivering high-quality and affordable biosimilar medicines to patients in need. It also removes the costs and uncertainty associated with protracted litigation.” He added that JHL will be able to continue to develop “the remainder, and majority” of its biosimilar pipeline, which includes omalizumab, pertuzumab, denosumab, ipilimumab, ustekinumab, and ramucirumab.
The trade secrets theft is also the subject of a criminal case, and Genentech continues to pursue a civil lawsuit against the individuals involved in the matter. A Genentech representative told The Center for Biosimilars® in an email that the settlement reached does not impact the government’s criminal case, and Genentech is currently on hold with its suit regarding the individual defendants until the criminal case has been resolved. The case is scheduled for trial in April 2020.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.